WebJan 7, 2024 · Positive Topline Data for TRANQUILITY Trial. On January 5, 2024, BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced positive topline results for the Phase 1b/2 TRANQUILITY trial of BXCL501 for the ... WebOct 18, 2024 · NEW HAVEN, Conn., Oct. 05, 2024 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. ( Nasdaq: BTAI ), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will host a Commercial Day presentation for the …
BioXcel Therapeutics Stock (NASDAQ:BTAI), Quotes and News …
WebApr 10, 2024 · BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product … WebFind the latest BioXcel Therapeutics, Inc. (BTAI) stock quote, history, news and other vital information to help you with your stock trading and investing. hotels yakima airport
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2024 ...
WebFind real-time BTAI - BioXcel Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. BTAI - BioXcel Therapeutics Inc Stock quote - … WebApr 6, 2024 · BioXcel Therapeutics press release (BTAI): Q4 GAAP EPS of -$1.95 misses by $0.51.Revenue of $0.24M misses by $0.84M.Cash and cash equivalents totaled … WebLatest BTAI News. View. BioXcel Therapeutics (BTAI, $18.66) Stochastic Oscillator left the oversold zone on March 31, 2024. Tickeron - Stocks • 2 days ago. BioXcel … hotels yangon myanmar burma